Medpace closed at $568.36, up by 1.45% in the latest trading session. This was better than the S&P 500, which rose by 0.88%, the Dow’s 0.38% increase, and the Nasdaq’s 1.31%. However, Medpace’s stock has dropped by 4.43% over the past month. In contrast, the Medical sector grew by 1.2% and the S&P 500 was up by 2.48%. The company is looking forward to its upcoming earnings report, predicting earnings per share (EPS) of $4.18, a 13.9% increase from last year. Revenue is expected to be $681.17 million, representing a 26.94% annual growth. For the year, forecasts suggest earnings of $14.79 per share and $2.5 billion in revenue, which are increases of 17.1% and 18.68%, respectively. Analyst changes in estimates may reflect a positive outlook for Medpace’s business. Importantly, Medpace holds a Zacks Rank of #2 (Buy), based on strong estimates that usually affect share prices. The Forward P/E ratio stands at 37.88, above the industry average of 15.44, while the PEG ratio is 2.11 compared to the industry’s 1.62. The Medical Services sector ranks 151 out of over 250 in the Zacks Industry Rank. Investors should use platforms like Zacks.com to stay updated. The recent 4.43% decline in a generally strong year for Medpace offers an interesting buying opportunity before the earnings report. Expectations for revenue and profit growth suggest that implied volatility in its options may be high. Thus, purchasing the stock outright at current levels carries significant risk if the company does not meet expectations. For those optimistic about the report, considering call options for January or February 2026 may be wise. This strategy allows investors to join a potential post-earnings rally while limiting risk to the premium paid. Historically, Medpace has consistently exceeded earnings estimates, beating them in the last four quarters reported through late 2025. However, it’s essential to be cautious about the stock’s high valuation. The Forward P/E ratio is more than double the industry average, which means any earnings disappointment could result in a sharp sell-off. Traders anticipating this scenario might explore buying put options as a direct way to benefit from potential declines in the upcoming weeks. Additionally, the broader economic context suggests caution. Although the global CRO market grew by over 11% in 2025, the higher interest rates since 2024 have limited funding for smaller biotech companies. This may pose risks for future contract growth, which the current stock price might not fully account for. A strategy that prepares for significant price movements in either direction, like a long straddle, could be suitable for the upcoming weeks. This involves purchasing both a call and a put option, profiting from substantial price changes regardless of direction. With market volatility, indicated by the VIX around 17 recently, the cost of this strategy could be reasonable for capturing a significant reaction after the earnings announcement.

here to set up a live account on VT Markets now